TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Immuron Limited ( (AU:IMC) ) is now available.
Immuron Limited announced a change in the director’s interest, with Dr. Jeannette Joughin acquiring an additional 1,000,000 unlisted options, bringing her total to 2,000,000. This change was approved by shareholders at the company’s Annual General Meeting, indicating a strategic alignment with the company’s growth objectives and potentially impacting its market positioning.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases. The company’s primary products are designed to target and modulate the immune system, offering potential treatments for a range of conditions.
Average Trading Volume: 538,302
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$17.23M
For an in-depth examination of IMC stock, go to TipRanks’ Overview page.